Charleston, SCNCT07526740Now EnrollingIRB Ready

Mild Cognitive Impairment (MCI) Clinical Trial in Charleston, SC

Access cutting-edge mild cognitive impairment (mci) treatment through this clinical trial at a research site in Charleston. Study-provided care at no cost to qualified participants.

Sponsored by Medical University of South Carolina

Quick Self-Assessment

See if you qualify for this Charleston location

Preparing your pre-screening questions…

Expert Care in Charleston

Access mild cognitive impairment (mci) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mild cognitive impairment (mci) treatment provided free

Apply for This Charleston Location

Check if you qualify for this mild cognitive impairment (mci) clinical trial in Charleston, SC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Charleston

    Convenient for SC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Charleston site if eligible
  4. 4Begin participation

About This Mild Cognitive Impairment (MCI) Study in Charleston

This is a randomized clinical trial of a treatment that combines non-invasive brain stimulation with computerized cognitive training (CCT) for people with mild cognitive impairment (MCI). The form of brain stimulation used in this study is accelerated intermittent theta burst stimulation (iTBS). All participants receive the same amount of iTBS and are randomly assigned to engage in one of two types of CCT. The goals of the study are to see if this combined treatment is feasible and acceptable to people with MCI and whether combined iTBS and CCT improves memory, thinking skills, mood, and daily function.

Sponsor: Medical University of South Carolina

Who Can Participate

Inclusion Criteria

Age 60-85 (inclusive).
English as a first/primary language.
Adequate sensorimotor function and verbal expressive abilities to complete all assessments.
Must have a co-participant (e.g. spouse, adult child or relative, sibling, cohabitator, friend, caregiver) who has at least weekly in-person contact with the participant and is willing to participate in the study as a collateral informant.
Meets the following requirements for current and prior medications and treatments:
Is on fixed pharmacotherapy (i.e. stable dose of medication/s) for ≥ 4 weeks before enrollment. This includes, but is not limited to, cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants.
Anti-amyloid monoclonal antibody therapy for AD/MCI:
Prior treatment is permitted if last infusion occurred ≥ 8 weeks before enrollment.
Current treatment is permitted if the dose has been stable for ≥ 12 weeks before enrollment, with no planned dose change during study participation.
Prior TMS treatment is permitted if the last stimulation session was ≥ 24 weeks before enrollment.
Documented diagnosis of MCI per NIA-AA criteria or Mild Neurocognitive Disorder per DSM-5 criteria by a healthcare provider within the past year, with a presumed etiology of possible or probable AD 7. Met actuarial neuropsychological criteria for MCI43 within the past year (i.e. ≥2 impaired scores within one cognitive domain, or ≥1 impaired scores in ≥3 domains, where an impaired score is defined as ≤16th percentile using appropriate demographically-corrected norms).

Exclusion Criteria

Telephone Interview for Cognitive Status (TICS) score of ≤ 22 suggestive of dementia.
Prior diagnosis of Dementia (NIA-AA) or Major Neurocognitive Disorder (DSM-5).
Daily/weekly anticholinergic or sedative use. Stimulants may be allowed pending investigator review.
History of significant or unstable condition/s or treatments for these condition/s that may impact cognition (as determined by the study investigators) such as significant cardiac (e.g. heart failure), infectious (e.g. HIV, urinary tract infection), or metabolic disease (e.g. labile diabetes), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), severe mental illness (e.g., bipolar disorder, psychoses), alcohol or substance use disorder, developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. movement disorder, multiple sclerosis, moderate to severe brain injury, seizures).
Plan to initiate treatment for AD/MCI with monoclonal antibody therapy during study participation.
For those currently receiving monoclonal antibody therapy, documented history of clinically significant amyloid-related imaging abnormalities (ARIA) in their medical record.
Current use of any implanted brain stimulation device.
Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days that may impact cognition or mood.
MRI contraindications (e.g., ferromagnetic implants, claustrophobia).
Unable or unwilling to engage in BrainHQ activities.
TMS contraindications (e.g., ferromagnetic implants, conditions or treatments that lower seizure threshold, taking medications that have short half-lives) or no identifiable motor threshold.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Charleston?

Yes, this clinical trial (NCT07526740) has an active research site in Charleston, SC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mild Cognitive Impairment (MCI) Treatment Options in Charleston, SC

If you're searching for mild cognitive impairment (mci) treatment options in Charleston, SC, this clinical trial (NCT07526740) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Charleston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mild cognitive impairment (mci) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mild cognitive impairment (mci) clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Charleston, SC

See all heart attack clinical trials recruiting in Charleston — not just this study.

Browse Heart Attack Trials in Charleston →

Browse More Trials by Condition

Heart Attack TrialsMyocardial Infarction TrialsInterstitial Lung Disease TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Charleston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Charleston, SC